1	WILLIAM BLUMENTHAL				
2	General Counsel				
3	PETER B. MILLER CHRISTINE J. LEE				
4	CA Bar No. 211462 Federal Trade Commission				
5	600 Pennsylvania Ave. NW, Room NJ-3212 Washington, DC 20580 (202) 326-2629 (Miller) (202) 326-2095 (Lee) (202) 326-3259 (fax)				
6	(202) 326-2629 (Miller) (202) 326-2095 (Lee)				
7					
8	JOHN D. JACOBS CA Bar No. 134154				
9	Federal Trade Commission 10877 Wilshire Boulevard, Suite 700				
10	Los Angeles, CA 90024 (310) 824-4360 (voice) (310) 824-4380 (fax)				
11					
12	ATTORNEYS FOR PLAINTIFF				
13	UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA				
14					
15	FEDERAL TRADE COMMISSION,				
16	Plaintiff,	CIVIL NUMBER			
17	v.	CV-04-8190-DSF (JTLx)			
18	WINDOW ROCK ENTERPRISES, INC.,	STIPULATED FINAL			
19	also d/b/a WINDOW ROCK HEALTH LABORATORIES, also d/b/a	AGREEMENT AND ORDER FOR PERMANENT			
20	CORTISLIM, INFINITY ADVERTISING, INC., STEPHEN F.	INJUNCTION AND SETTLEMENT OF			
21	CHENG, SHAWN M. TALBOTT, and GREGORY S. CYNAUMON,	CLAIMS FOR MONETARY RELIEF AS TO			
22	PINNACLE MARKETING CONCEPTS, INC., also d/b/a PMC HEALTH	DEFENDANTS INFINITY ADVERTISING,			
23	PRODUCTS, AND THOMAS F. CHENG	INC. AND GREGORY S. CYNAUMON			
24	Defendants.				
25	The Federal Trade Commission ("Commission") filed a complaint,				
26	subsequently amended (as amended, "Complaint"), pursuant to Section 13(b) of				
27	the Federal Trade Commission Act ("FTC Ac	et"), 15 U.S.C. § 53(b), to secure			
28					

1	permanent injunctive relief, restitution, disgorgement, and other equitable relief	
2	against the Defendants for their alleged deceptive acts or practices and false	
3	advertisements in connection with the advertising, promotion, and sale of an	
4	alleged weight-loss product, "CortiSlim," and an alleged stress-relief product,	
5	"CortiStress," in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C.	
6	§§ 45(a) and 52.	
7	The Commission and Defendants Infinity Advertising, Inc. and Gregory S.	
8	Cynaumon (collectively, "Stipulating Defendants"), without Stipulating	
9	Defendants admitting or denying liability for any of the conduct alleged in the	
10	Complaint, have stipulated to entry of the following agreement for permanent	
11	injunction and settlement of claims for monetary relief in settlement of the	
12	Commission's Complaint against Stipulating Defendants.	
13	The Court, having been presented with this Stipulat@amen ;iiames. 44220800	
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		

Act, 28 U.S.C. § 2412, concerning the prosecution of this action to the date of this Order.

- 5. Stipulating Defendants have entered into this Order freely and without coercion.
- 6. The Commission and Stipulating Defendants stipulate and agree to this Order, without trial or final adjudication of any issue of fact or law, to settle and resolve all matters in dispute between them arising from the Complaint up to the date of entry final adj

- 12. This Order replaces, with regard to Stipulating Defendants, the Stipulated Interim Agreement and Order lodged on September 30, 2004, and entered on October 7, 2004 ("Stipulated Interim Order").
 - 13. Each party shall bear its own costs and attorneys' fees.
 - 14. Entry of this Order is in the public interest.

DEFINITIONS

For the purposes of this Order, the following definitions shall apply:

- 1. Unless otherwise specified,
 - a. "Infinity" shall mean defendant Infinity Advertising, Inc.;
 - b. "Gregory Cynaumon" shall mean defendant Gregory S.
 Cynaumon, individually and in his capacity as an officer of Infinity; and
 - c. "Stipulating Defendant(s)" shall mean one or both of Infinity and Gregory Cynaumon.
- 2. "Advertising" and "promotion" shall mean any written or verbal statement, illustration, or depiction designed to effect a sale or create interest in the purchasing of goods, whether it appears in a brochure, newspaper, magazine, pamphlet, leaflet, circular, mailer, book insert, free standing insert, letter, catalogue, poster, chart, billboard, public transit card, point of purchase display, packaging, package insert, label, film, slide, radio, television or cable television, audio program transmitted over a telephone system, program-length commercial ("infomercial"), the Internet, email, press release, video news release, or in any other medium.
- 3. "Assisting others" shall mean knowingly providing any of the following services to any person or entity engaged in conduct related to the subject matter of this Order, including the sale or marketing of a Target Product or a

5

6

7 8

10 11

9

12 13

14 15

16 17

18

19 20

21

22

23

24

25

26

27 28

Covered Product: (a) serving as an owner, partner, officer, director or manager of a business entity selling or marketing a Target Product or a Covered Product; (b) formulating or providing, or arranging for the formulation or provision of, any Covered Product or any advertising for any Covered Product; or c) appearing in any advertising for any Covered Product.

- "Commerce" shall mean as defined in Section 4 of the FTC Act, 15 4. U.S.C. § 44.
- "Competent and reliable scientific evidence" shall mean tests, 5. analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area that has been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the professions to yield accurate and reliable results.
- "CortiSlim" shall mean the dietary supplement CortiSlim and any 6. other product that
 - contains one or more of the following ingredients present in a. current or previous formulations of CortiSlim: magnolia bark extract, beta-sitosterol, theanine, green tea leaf extract, bitter orange peel extract, Panax ginseng, banaba leaf extract, chromium, or vanadium; and
 - is marketed with claims that it has a weight effect or reduces or b. manages stress.
- 7. "CortiSlim Study" shall mean the study conducted by Defendant Talbott and others as reported, at least in part, under the title "Effect of a Stress/Cortisol-Control Dietary Supplement on Weight Loss," by Shawn Talbott, Ann-Marie Christopulos, and Jill Whelan, as well as all underlying data for such study.

1
 2
 3

16. A requirement that Stipulating Defendants "notify," "furnish," "provide," or "submit" to the Commission shall mean that Stipulating Defendants shall send the necessary information via **overnight courier**, costs prepaid, to:

Associate Director for Enforcement Federal Trade Commission 600 Pennsylvania Avenue, N.W. Washington, DC 20580 Attn: *FTC v. Window Rock Enterprises, Inc., et al.,* (C.D. Cal.), Civ. No. 04-8190-DSF (JTLx).

- 17. The terms "and" and "or" in this Order shall be construed conjunctively or disjunctively as necessary, to make the applicable sentence or phrase inclusive rather than exclusive.
- 18. The term "including" in this Order shall mean "including without limitation."

IT IS STIPULATED, AGREED, AND ORDERED THAT:

I.

PROHIBITED REPRESENTATIONS REGARDING ANY TARGET PRODUCT

A. Stipulating Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other entity, and their officers, agents, servants, employees, and all persons and entities in active concert or participation with them who receive actual notice of this Order by personal service, facsimile, or otherwise, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Target Product, in or affecting commerce, are hereby permanently restrained and enjoined from making, or assisting others in making, directly or by implication, including through the use of endorsements or product names, any representation that any Target Product:

- 1. Reduces the risk of or prevents serious health conditions, including osteoporosis, obesity, diabetes, Alzheimer's disease, cancer, and cardiovascular disease;
- 2. Causes weight loss of 10 to 50 pounds or more for virtually all users;
- 3. Causes users to lose as much as 4 to 10 pounds per week over multiple weeks;
- 4. Causes users to lose weight specifically from the abdomen, stomach, and thighs;
- 5. Causes rapid and substantial weight loss;
- 6. Causes long-term or permanent weight loss;
- 7. Causes weight loss without the need for diet or exercise; or
- 8. Has been demonstrated effective, is supported by, or is otherwise the product of over 15 years of scientific research.
- B. Stipulating Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other entity, and their officers, agents, servants, employees, and all persons and entities in active concert or participation with them who receive actual notice of this Order by personal service, facsimile, or otherwise, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Target Product, in or affecting commerce, are hereby permanently restrained and enjoined from making, or from assisting others in making, directly or by implication, including through the use of endorsements or product names, any other representation about the performance or efficacy of any Target Product unless the representation is true and non-misleading, and, at the time it is made, Stipulating Defendants possess and rely upon competent and reliable scientific evidence that substantiates the representation.

PROHIBITED REPRESENTATIONS REGARDING ANY COVERED PRODUCT

Stipulating Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other entity, and their officers, agents, servants, employees, and all persons and entities in active concert or participation with them who receive actual notice of this Order by personal service, facsimile, or otherwise, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product, in or affecting commerce, are hereby permanently restrained and enjoined from making, or assisting others in making, directly or by implication, including through the use of endorsements or product names, any representation about the weight effect, other health benefits, performance, or efficacy of any Covered Product unless the representation is true and non-misleading, and, at the time it is made, Stipulating Defendants possess and rely upon competent and reliable scientific evidence that substantiates the representation.

III.

PROHIBITED REPRESENTATIONS REGARDING TESTS AND STUDIES

Stipulating Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other entity, and their officers, agents, servants, employees, and all persons and entities in active concert or participation with them who receive actual notice of this Order by personal service, facsimile, or otherwise, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product, in or affecting commerce, are hereby permanently restrained and enjoined from making or assisting others in making, directly or by implication, including through the use

of endorsements or product names, any misrepresentation about the existence, contents, validity, results, conclusions, or interpretations of any test or study including, but not limited to, the CortiSlim Study. IV. FORMATTING AND DISCLOSURES FOR BROADCAST MEDIA Stipulating Defendants, directly or through any corporation, partnership, subsidiary, division, trade name, or other entity, and their officers, agents, servants, employees, and all persons and entities in active concert or participation with them who receive actual notice of this Order by personal service, facsimile, or otherwi**senstibits28** of **.682n0086**a Tide, 660086 Tic, co accatiladore, enta 48t, Tddvt or pa 91 82 0 Tayos

S

t

"YOU ARE WATCHING A PAID ADVERTISEMENT FOR [THE PRODUCT, PROGRAM, OR SERVICE]." Provided that, for the purposes of

A. For any product that is specifically permitted in labeling for such product by regulations promulgated by the Food and Drug Administration pursuant to the Nutrition Labeling and Education Act of 1990;

- B. For any drug that is permitted in labeling for such drug under any tentative final or final standard promulgated by the Food and Drug Administration, or under any new drug application approved by the Food and Drug Administration; or
- C. For any medical device that is permitted in labeling of such medical device under any medical device-specific regulation promulgated by the Food and Drug Administration, under any Federal Food, Drug and Cosmetic Act Section 510(k) premarket notification substantial equivalence determination by the Food and Drug Administration, or under any premarket approval application approved by the Food and Drug Administration.

VI.

MONETARY JUDGMENT AND CONSUMER REDRESS

Judgment for equitable monetary relief is hereby entered against Stipulating Defendants, jointly and severally, in the amount of nineteen million dollars (\$19,000,000). *Provided, however*, that this judgment shall be suspended and, subject to the provisions of Part VII, shall be deemed to be fully satisfied upon completion of the requirements in paragraphs A, B, C, D, and I of this Part, below:

A. Transfer to the Commission of two hundred thousand dollars (\$200,000) cash, which amount is currently being held in escrow by undersigned counsel for Stipulating Defendants and which amount shall remain in escrow and shall not be disbursed, transferred, or otherwise expended except in accordance with this Part. The Settlement Payment shall be released from the escrow and transferred to the Commission by electronic funds transfer no later than five (5)

- B. Waiver of all claim to, unconditional release of, and consent to transfer to the Commission of all funds held by this Court pursuant to the Rule 67 Order entered by this Court on or about July 26, 2006, pursuant to Fed. R. Civ. P. 67 and L.R. 67-1 and 67-2, not later than five (5) business days after the date of entry of this Order and in accordance with directions provided by the Commission. These funds consist of the two million five hundred thousand dollars (\$2,500,000) disbursed by the bankruptcy estate of Window Rock to the Clerk of this Court, plus any accrued interest, less any deductions permitted by Fed. R. Civ. P. 67.
- Transfer to the Commission, no later than ninety (90) days after the date of entry of this Order and in accordance with transfer directions provided by the Commission, the Stipulating Defendants' choice of either i) net proceeds, up to a maximum of eight hundred thousand dollars (\$800,000), from the arm's-length sale at prevailing market price to an unrelated buyer of the property located in Tustin, California ("Tustin Property"), where "net proceeds" shall mean "sales price less all reasonable and customary costs, fees, and expenses associated with sales of real property," and the sales documents, including but not limited to the HUD-1 statement, shall be provided for the Commission's review; or ii) legal title to, and move out and surrender of physical possession of, the Tustin Property, with Stipulating Defendants responsible for procuring all signatures necessary to convey to the Commission legal and marketable title to the Tustin Property, without regard to whether the conveying entities or individuals are party to this Order. The Tustin Property was acquired by Gregory Cynaumon with assets derived from the marketing or sale of CortiSlim and CortiStress and is described more fully in the document entitled "Additional Representations by Stipulating Defendants," which has been provided separately to the Commission, is

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

20 -1.682 df84s

transfer to the Commission of the proceeds from the sale, up to a maximum of eight hundred thousand dollars (\$800,000) in proceeds;

- b. If Stipulating Defendants transfer to the Commission legal and marketable title to the Tustin Property and vacate and surrender the premises to the Commission, in compliance with all requirements of this paragraph C, the Commission shall, after verifying title, the current status of all payments on the Tustin Property, and the condition of the premises, release any claim the Commission has to the Tustin Deposit; and
- c. If the Stipulating Defendants are not in compliance with the requirements of this paragraph C, the Commission shall, upon written demand, receive some or all of the Tustin Deposit to the extent necessary to bring the Tustin Property into compliance with the requirements of this paragraph C.
- D. Transfer to the Commission of the Net Contribution to an investment partnership and related charitable foundations, which were established by or on behalf of Gregory Cynaumon with assets derived from the marketing or sale of CortiSlim and CortiStress, which shall be funded in an amount of not less than two million seven hundred thousand dollars (\$2,700,000) on the date of entry of this Order, all as described more fully in the document entitled "Additional Representations by Stipulating Defendants." For purposes of this Part, "Net Contribution" shall mean all proceeds from the contributions to the investment partnership and related charitable foundation that remain from the two million seven hundred thousand dollars (\$2,700,000) after payment of federal and state

taxes, federal and state penalties, and other costs (but excluding costs and professional fees paid to any of the entities and individuals involved in establishing, maintaining, or managing the investment partnership and charitable foundation) directly associated with revoking the contributions, unwinding the business transactions, dissolving the entities, or taking other similar steps necessary to recover the contributions. *Provided, however*, that all such taxes, penalties, and costs shall be subject to review, audit, and challenge by the Commission. Any such Net Contribution shall not be disbursed, transferred, or otherwise expended except in accordance with this Part. Any such Net Contribution shall be transferred to the Commission by electronic funds transfer no more than one hundred and eighty (180) days after the date of entry of this Order and in accordance with directions provided by the Commission.

E. Stipulating Defendants hereby assign to the Commission, without any encumbrances, all rights and claims to money or other assets owed to them as of the date of entry of this Order by a Related Party, and of the right to pursue any chose in action to recover any such money or assets owed to them by a Related Party, under the terms of any agreement, oral or written, including but not limited to the Joint Venture Agreement entered into on June 10, 2003 by and between Defendants Shawn Talbott and Window Rock, the Joint Venture Agreement entered into on June 21, 2003 by and between Window Rock and Stipulating Defendants, and the purported non-written agreement by and between Defendants Window Rock and Pinnacle. *Provided, however*, that this assignment shall not include any rights, claims, assets, and rights to pursue any chose in action that are settled, extinguished, or otherwise resolved by final order in Window Rock's bankruptcy case.

9

1213

15

14

17

16

1819

20

21

2223

2425

2627

F. If any Related Party assigns to the Commission rights of recovery and claims to money or other assets purportedly owed to it as of the date of entry of this Order by any Stipulating Defendant, the Commission shall not exercise any such rights and claims in a manner that would allow it to recover additional funds from any Stipulating Defendant; *provided, however*, that this paragraph F shall cease to apply upon occurrence of any of the events described under Part VII.

G. All funds paid to the Commission pursuant to this Order shall be deposited into an account administered by the Commission or its agent to be used for equitable relief, including but not limited to consumer redress for nationwide sales of CortiSlim and CortiStress from the time those products were first advertised up to and including May 31, 2006, and any attendant expenses for the administration of such equitable relief. In the event that direct redress to consumers is wholly or partially impracticable or funds remain after redress is completed, the Commission may apply any remaining funds for such other equitable relief (including consumer information remedies) as it determines to be reasonably related to the practices alleged in the Complaint. Any funds not used for such equitable relief shall be deposited to the United States Treasury as disgorgement. Stipulating Defendants shall have no right to challenge the Commission's choice of remedies under this Part. Stipulating Defendants shall have no right to contest the manner of distribution chosen by the Commission. No portion of any payments under the judgment herein shall be deemed a payment of any fine, penalty, or punitive assessment;

H. Stipulating Defendants relinquish all dominion, control, and title to the funds paid into the account established pursuant to this Order, and all legal and equitable title to the funds shall vest in the Treasurer of the United States unless and until such funds are disbursed to consumers. Stipulating Defendants shall make no claim to or demand for the return of the funds, directly or indirectly,

5

6

7

8

9

10

11

12

13

14

15

16

through counsel or otherwise, and in the event of a subsequent bankruptcy case involving a Stipulating Defendant, Stipulating Defendants acknowledge that the funds are not part of any bankruptcy estate and that no bankruptcy estate has any claim or interest therein; and

I. Each Stipulating Defendant shall provide to the Commission a sworn statement setting forth i) the amount of 2003, 2004, and 2005 state and federal taxes, if any, that have been paid on or before the date that the Stipulating Defendants signed this Order; ii) the amount of 2005 and 2006 estimated state and federal tax payments, if any, that have been paid on or before the date that the Stipulating Defendants signed this Order; and iii) a statement of the date(s) on which each tax payment to a state or federal tax authority was made. All 2003, 2004, and 2005 tax payments and any 2006 estimated tax payments that are reported to the Commission as being owed to a state or federal tax authority shall be paid in full no later than sixty (60) days from the date of entry of this Order. The financial information and documents referenced in this paragraph I shall be designated as confidential.

17

18

19 20

21

22

23

24

25

By agreeing to this Order, Stipulating Defendants reaffirm and attest A. to the truthfulness, accuracy, and completeness of the financial information that they have previously submitted to the Commission. The Commission's agreement to this Order is expressly premised upon the truthfulness, accuracy, and completeness of Stipulating Defendants' financial statements and other information that they submitted to the Commission, namely:

VII.

RIGHT TO REOPEN

26

1. April 12, 2005 letter from Venable LLP to FTC, with attachments

1 | 1 | 2 | 0 | 3 | 0 | 4 | 8 | 5 | 0 | 6 | 8 | 9 |

material asset, or materially misrepresented the value of any asset, or made any other material misrepresentation in or omission from the Financial Statements or other supporting documents listed in this Part, the Court shall reinstate the suspended judgment in Part VI, above, in the amount of nineteen million dollars (\$19,000,000), less any amount already paid to the Commission by or on behalf of Stipulating Defendants.

- 1. *Provided, however,* that in all other respects this Order shall remain in full force and effect unless otherwise ordered by the Court; and
- 2. *Provided, further*, that proceedings instituted under this Part would be in addition to, and not in lieu of, any other civil or criminal remedies as may be provided by law, including any other proceedings that the Commission may initiate to enforce this Order.
- B. Solely for purposes of this Part, Stipulating Defendants waive any right to contest any of the allegations in the Complaint and agree that the facts as alleged in the Complaint shall be taken as true, without further proof, in any subsequent litigation filed by or on behalf of the Commission to enforce its rights pursuant to this Part. Except for the amount of the judgment, the financial information and documents referenced in this Part shall be designated as confidential and shall be disclosed only as necessary for enforcement purposes.
- C. In agreeing to this Order, the Commission has specifically relied on the representations that Stipulating Defendants have made regarding the amount of federal and state taxes, if any, that have been or will be paid for tax years 2003, 2004, and 2005, and the amount of estimated federal and state taxes, if any, that have been paid toward estimated taxes for tax years 2005 and 2006, including but not limited to representations in the documents referenced in Part VI.I, above, and

25

26

27

28

in the documents listed in paragraph A of this Part. All federal and state tax returns, amended returns, and other documents filed with the IRS and/or state tax authorities on or after the date that the Stipulating Defendants signed this Order involving tax years 2003, 2004, 2005, and 2006 shall be prepared and signed by a third-party independent CPA accounting firm, and a copy of any and all such returns, amended returns, and other documents, complete with all attachments, shall be provided to the Commission at the time they are submitted to the state or federal tax authority.

- 1. It shall be a violation of this Part for Stipulating Defendants to file any federal or state tax return seeking a cash refund of some or all of the amounts previously reported to the Commission as taxes owed and paid for tax years 2003, 2004, and 2005 or seeking a cash refund of some or all of the amounts paid toward estimated taxes for tax year 2006. *Provided, however,* that seeking such a cash refund shall not be deemed to be a violation of this Part if Stipulating Defendants promptly remit to the Commission the full amount of any such cash refund within ten (10) days of receipt of the refund.
- 2. It shall be a violation of this Part for Stipulating Defendants (or any entity owned directly or indirectly by one or more of the Stipulating Defendants) to claim a tax deduction on any federal or state tax return (including amended returns) for the \$2,500,000 described in Part VI.B, above. *Provided, however,* that it shall not be a violation of this Part for Stipulating Defendants to claim a tax deduction for the \$2,500,000
 - On their federal tax return(s), but only to the extent that a. they report to the Internal Revenue Service the

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	(
19	t
19 20 21	u
21	
22	
23	

25

26

27

28

\$2,500,000 as taxable income or gain and do not subsequently seek to change this reported amount or its treatment for tax purposes; and

- b. On their state tax return(s), but only to the extent that they report to the California Franchise Tax Board the \$2,500,000 as taxable income or gain and do not subsequently seek to change this reported amount or its treatment for tax purposes; and
- 3. It shall be a violation of this Part for Stipulating Defendants (or any entity owned directly or indirectly by one or more of the Stipulating Defendants) to claim a tax deduction on any federal or state tax return (including amended returns) for the Net Contribution described in Part VI.D, above.

VIII.

ACKNOWLEDGMENT OF RECEIPT OF ORDER

Within five (5) business days after receipt of this Order as entered by the Court, Gregory Cynaumon, individually and on behalf of Infinity, shall submit to the Commission a truthful sworn statement acknowledging receipt of this Order, using the form shown at Attachment A.

IX.

DISTRIBUTION OF ORDER

For a period of three (3) years from the date of entry of this Order, Stipulating Defendants shall deliver copies of this Order as directed below:

A. Infinity shall deliver a copy of this Order to all of its principals, officers, directors, and managers and also to all of its supervisory employees,

of this Order as required by this Part. X. **COMPLIANCE MONITORING** For the purpose of monitoring compliance with any provision of this Order, Wit A.

	1
	2
	3
	4
	5
	6
	7
	8
	9
1	0
1	1
1	2
1	3
1	4
1	5
1	6
1	7
1	8
1	9
2	0
2	1
2	2
2	3
2	4
2	5
2	6

28

C. Stipulating Defendants, upon fourteen (14) days notice, shall permit representatives of the Commission to interview any officer, director, employee, employer, consultant, independent contractor, representative, or agent of any entity managed or controlled in whole or in part by either or both Gregory Cynaumon or Infinity who has agreed to such an interview, relating in any way to any conduct subject to this Order. The person interviewed may have counsel present.

D. *Provided, however*, that nothing in this Order shall limit the Commission's lawful use of compulsory process, pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49, 57b-1, to obtain any documentary material, tangible things, testimony, or information relevant to unfair or deceptive acts or practices in or affecting commerce (within the meaning of 15 U.S.C. § 45(a)(1)).

XI.

- B. For a period of three (3) years from the date of entry of this Order,
 - 1. Infinity shall notify the Commission of any changes in its corporate structure or in any business entity that it directly or indirectly control(s), or has an ownership interest in, that may affect compliance obligations arising under this Order, including but not limited to a dissolution, assignment, sale,

	3
	4
	5
	6
	7
	8
	9
1	0
1	1
1	2
1	3
1	4
1	5
1	6
1	7
1	8
1	9
2	0
2	1
2	2
2	3
2	4
2	5
2	6
2	7
2	8

2

change. Such notice shall include the name and address of each business that he is affiliated with, employed by, creates or forms, or performs services for; a statement of the nature of the business; and a statement of his duties and responsibilities in connection with the business; and

- c. Any changes in his name or use of any aliases or fictitious names.
- C. Ninety (90) days after the date of entry of this Order, each Stipulating Defendant shall provide a written report to the Commission, sworn to under penalty of perjury, setting forth in detail the manner and form in which they have complied and are complying with this Order. This report shall include, but not be limited to, any changes required to be reported pursuTjat8i and ar759

Defendants, with contemporaneous notice to undersigned counsel or to any other counsel for Stipulating Defendants whose identity has been furnished to the Commission.

F. The information and documents referenced in paragraphs A, B, and D of this Part shall be designated as confidential.

XII.

RECORD-KEEPING PROVISIONS

For a period of five (5) years from the date of entry of this Order,
Stipulating Defendants and their agents, employees, officers, corporations,
successors, and assigns, and those persons in active concert or participation with
them who receive actual notice of this Order by personal service or otherwise, if
engaging or assisting others engaged in the manufacturing, labeling, advertising,
promotion, offering for sale, sale, or distribution of any Covered Product, in or
affecting commerce, and any business whereafte Tell (2021) 25:0983 (107 probling) 155.0007 [20]

reason for the person's termination, if applicable;


- C. Customer files containing the names, addresses, telephone numbers, dollar amounts paid, quantity of items purchased, and description of items purchased, to the extent such information is obtained in the ordinary course of business;
- D. Complaints and refund requests (whether received directly, indirectly or through any third party), and any response to those complaints or requests;
- E. Copies of all advertisements, promotional materials, sales scripts, training materials, or other marketing materials utilized in the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product, to the extent such information is prepared in the ordinary course of business;
- F. All documents evidencing or referring to the accuracy of any claim or representation contained in the materials identified in paragraph E of this Part, or to the efficacy of any Covered Product, including, but not limited to, all tests, reports, studies, and demonstrations, as well as all evidence that confirms, contradicts, qualifies, was relied upon in making, or calls into question the accuracy of such claims;
- G. Records accurately reflecting the name, address, and telephone number of each manufacturer or laboratory engaged in the development or creation of any testing obtained for the purpose of manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product; and
- H. All records and documents necessary to demonstrate full compliance with each provision of

XIII.

COOPERATION WITH COMMISSION COUNSEL

A. Stipulating Defendants shall, in connection with the unwinding of the charitable foundation and its related limited partnership described in paragraph VI.D, above, and in cooperation with the Commission: request the voluntary unwinding of these entities and request the trustees, agents, or representatives of these entities to cooperate in this voluntary unwinding; initiate communications for the purposes of unwinding these entities with State or Federal authorities; cooperate in good faith with the Commission's reasonable requests for documents and writings and testimony in connection with the unwinding of these entities; and, if necessary, appear in person or through their representatives at such places and times or execute such documents as the Commission shall reasonably request after written notice to Stipulating Defendants and their counsel of reduktures write of the content of the con





ATTACHMENT A

UNITED STATES DISTRICT COURT

CENTRAL DISTRICT OF CALIFORNIA

1 2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2122

2324

25

26

27

28

FEDERAL TRADE COMMISSION.

Plaintiff,

v.

WINDOW ROCK ENTERPRISES, INC., also d/b/a WINDOW ROCK HEALTH LABORATORIES, also d/b/a CORTISLIM, INFINITY ADVERTISING, INC., STEPHEN F. CHENG, SHAWN M. TALBOTT, GREGORY S. CYNAUMON, PINNACLE MARKETING CONCEPTS, INC., AND THOMAS F. CHENG

Defendants.

CIVIL NUMBER

CV-04-8190-DSF (JTLx)

DECLARATION OF DEFENDANT GREGORY S. CYNAUMON UNDER 28 U.S.C. § 1746

GREGORY S. CYNAUMON declares as follows:

- 1. My name is Gregory S. Cynaumon. My current residence is
 ______. I am a citizen of the United States and am over the age of eighteen. I have personal knowledge of the facts set forth in this Declaration.
- 2. I am an individual defendant in the above-captioned case, *FTC v*. *Window Rock Enterprises, Inc. et al.* I am also an officer of Infinity Advertising, Inc., which is also a defendant in that case.
- 3. On [DATE], I received, individually and in my capacity as an officer of Infinity Advertising, Inc., a copy of the Stipulated Final Agreement and Order for Permanent Injunction and Settlement of Claims for Monetary Relief as to Defendants Infinity Advertising, Inc. and Gregory S. Cynaumon, which was entered by the Court on [DATE] ("Order"). A true and correct copy of the Order is attached to this Declaration.